TENAX THERAPEUTICS INC
For the period ended Dec 31, 2023. Filed Mar 28, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 28, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
ITEM 16. —FORM 10-K SUMMARY
None.
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| Date: March 28, 2024 | TENAX THERAPEUTICS, INC. | |
|---|---|---|
| By: | /s/ Lawrence R. Hoffman | |
| Lawrence R. Hoffman Interim Chief Financial Officer(On behalf of the Registrant and as Principal Financial and Accounting Officer) | ||
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.
| Name | Title | Date |
|---|---|---|
| /s/ Christopher T. Giordano | President and Chief Executive Officer and Director | March 28, 2024 |
| Christopher T. Giordano | (Principal Executive Officer) | |
| /s/ Lawrence R. Hoffman | Interim Chief Financial Officer | March 28, 2024 |
| Lawrence R. Hoffman | (Principal Financial Officer and Principal Accounting Officer) | |
| /s/ Gerald Proehl | Chairman of the Board and Director | March 28, 2024 |
| Gerald Proehl | ||
| /s/ June Almenoff, MD | Director | March 28, 2024 |
| June Almenoff, MD | ||
| /s/ Michael Davidson, MD | Director | March 28, 2024 |
| Michael Davidson, MD | ||
| /s/ Declan Doogan, MD | Director | March 28, 2024 |
| Declan Doogan, MD | ||
| /s/ Robyn M. Hunter | Director | March 28, 2024 |
| Robyn M. Hunter | ||
| /s/ Stuart Rich, MD | Director | March 28, 2024 |
| Stuart Rich, MD | ||
INDEX TO CONSOLIDATED FINANCIAL STATEMENTS
| REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM (PCAOB ID: 00677) | F-2 |
|---|---|
| CONSOLIDATED BALANCE SHEETS | F-4 |
| CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS | F-5 |
| CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY | F-6 |
| CONSOLIDATED STATEMENTS OF CASH FLOWS | F-7 |
| NOTES TO CONSOLIDATED FINANCIAL STATEMENTS | F-8 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.